'Cvd events' diaporamas de présentation

Outline

Hyperlipidemia Management in T2DM Changing Diabetes Mellitus to Diabetes Lipidus Dr.Wehad ALTourah Consultant Internist, Assistant Director Internal Medicine Residency training Program FRCP(London),KBIM Amiri Hospital. Outline. Cases Epidemiology and cardiovascular risk

1.47k views • 124 slides

*National Lipid Association Consensus Panel on Biomarker Testing August Orlando, Florida

Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists. *National Lipid Association Consensus Panel on Biomarker Testing August Orlando, Florida. The Markers. Chairpersons. Authors/Panelists. Presenters.

909 views • 90 slides

Clinical aspects of managing the cardiovascular risk in diabetes Dr SH Song MD FRCP

Clinical aspects of managing the cardiovascular risk in diabetes Dr SH Song MD FRCP Consultant Diabetologist Northern General Hospital Sheffield. Increased CHD in type 1 diabetes. Laing at al Diabetologia 2003; 46: 760-5. STENO-2 Evidence - Intensive multifactorial intervention are

675 views • 53 slides

916 views • 46 slides

Cholesterol from the blood gets into the artery wall and is primary cause of Atherosclerosis

Reversing Atherosclerosis and Preventing CVD Events with a Low-Fat Diet & Exercise Program James J. Kenney, PhD, FACN (Nutrition Research Specialists, Pritikin Longevity Center). Cholesterol from the blood gets into the artery wall and is primary cause of Atherosclerosis.

586 views • 38 slides

ADA & ACC Consensus Statement Lipoprotein Management in Patients with Cardiometabolic Risk

ADA & ACC Consensus Statement Lipoprotein Management in Patients with Cardiometabolic Risk. Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey New Jersey Medical School

529 views • 37 slides

QRISK: a new CVD risk score development & validation Julia Hippisley-Cox Calgary 23 Oct 2007

QRISK: a new CVD risk score development & validation Julia Hippisley-Cox Calgary 23 Oct 2007. Acknowledgments coauthors . Carol Coupland statistician Yana Vinogradova statistician John Robson GP Margaret May statistician Peter Brindle GP. Acknowledgments. EMIS practices

740 views • 25 slides

Prevention of cardiovascular disease at population level

Prevention of cardiovascular disease at population level. Implementing recommendations for practice. June 2010. NICE public health guidance 25. What this presentation covers. Background Recommendations for practice Costs and savings Discussion Find out more. Background.

397 views • 22 slides

William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN

Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.

303 views • 18 slides

William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN

Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.

189 views • 18 slides

Adrianna Murphy, M.Sc .

Using Community Health Workers to Manage Hypertension in Urban India: A Cost-Effectiveness Analysis. Adrianna Murphy, M.Sc . London School of Hygiene and Tropical Medicine; Harvard School of Public Health Joshua Schulman-Marcus, M.D . Columbia University Medical School

262 views • 16 slides

When is enough is enough? appropriate care at the end of life

When is enough is enough? appropriate care at the end of life. Ngaire Kerse, PhD, MBChB. Professor, General Practice and Primary Health Care, University of Auckland . NATURE|Vol 464|25 March 2010| doi:10.1038/nature08984.

261 views • 14 slides

The ACCORD Trial: Review of Design and Results

The ACCORD Trial: Review of Design and Results. Highlights from presentations made at the ADA 68 th Scientific Sessions, June 10, 2008. ACCORD Glycemia Research Question and Study Design. Glycemia Research Question:

175 views • 14 slides

Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups

ALLHAT. ALLHAT Revisited How have the Initial Findings Held Up Five Years Later?. Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups. Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood, Illinois, U.S.A. ALLHAT.

208 views • 12 slides

Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups

ALLHAT. ALLHAT Revisited How have the Initial Findings Held Up Five Years Later?. Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups. Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood, Illinois, U.S.A. ALLHAT.

125 views • 12 slides

Franklin SS, et al. Circulation 2009;119:243-50

Franklin SS, et al. Circulation 2009;119:243-50. Descriptive and Baseline Characteristics of Framingham Original and Offspring Cohort. Franklin SS, et al. Circulation 2009;119:243-50. Frequency Distribution of CVD Events per Number of Person-Observations by SBP and DBP Groups.

247 views • 10 slides

Hamer M, et al. J Am Coll Cardiol 2008;52:2156-62

Hamer M, et al. J Am Coll Cardiol 2008;52:2156-62. Descriptive Characteristics of Participants at Baseline by Psychological Distress. Hamer M, et al. J Am Coll Cardiol 2008;52:2156-62.

51 views • 4 slides